Midazolam
Buccolam, Midazolam, Midozalam, Nayzilam, Seizalam (midazolam) is a small molecule pharmaceutical. Midazolam was first approved as Versed on 1985-12-20. It is used to treat anxiety disorders, psychomotor agitation, and status epilepticus in the USA. It has been approved in Europe to treat epilepsy. It is known to target alpha-1B adrenergic receptor and thyrotropin-releasing hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Midazolam, Midozalam, Nayzilam, Seizalam (discontinued: Midazolam, Versed)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Midazolam hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SEIZALAM | Meridian Medical Technologies | N-209566 RX | 2018-09-14 | 1 products, RLD, RS |
Show 3 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| midazolam | ANDA | 2024-10-29 |
| midazolam hcl | unapproved drug other | 2016-04-06 |
| midazolam hydrochloride | ANDA | 2024-10-21 |
| midazolam in sodium chloride | ANDA | 2024-08-16 |
| mkh dose pack | unapproved drug other | 2019-03-05 |
| mko melt dose pack | unapproved drug other | 2019-03-04 |
| n/a | New Drug Application | 2024-05-09 |
| nayzilam | New Drug Application | 2023-01-19 |
| seizalam | New Drug Application | 2023-01-26 |
| versed guards up daily mineral sunscreen broad spectrum spf 35 | OTC monograph final | 2022-08-30 |
Show 1 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psychomotor agitation | — | D011595 | — |
| status epilepticus | EFO_0008526 | D013226 | G41 |
| anxiety disorders | EFO_0006788 | D001008 | F41.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MIDAZOLAM, NAYZILAM, UCB INC | |||
| 2026-05-17 | ODE-243 | ||
MIDAZOLAM HYDROCHLORIDE, SEIZALAM, MMT | |||
| 2025-09-14 | ODE-207 | ||
HCPCS
Code | Description |
|---|---|
| J2250 | Injection, midazolam hydrochloride, per 1 mg |
Clinical
Clinical Trials
1510 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 181 | 1 | 1 | 2 | 6 | 191 |
| Anesthesia | D000758 | — | — | 3 | 2 | 7 | 19 | 22 | 51 |
| Postoperative pain | D010149 | — | G89.18 | 3 | 7 | 4 | 15 | 25 | 50 |
| Neoplasms | D009369 | — | C80 | 34 | 3 | 1 | 2 | 8 | 46 |
| Depression | D003863 | — | F33.9 | 9 | 15 | 8 | 7 | 8 | 41 |
| Delirium | D003693 | — | R41.0 | 4 | 1 | 3 | 15 | 17 | 40 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | 6 | 2 | 13 | 18 | 39 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 8 | 13 | 6 | 8 | 7 | 37 |
| Pain | D010146 | EFO_0003843 | R52 | 7 | 3 | — | 10 | 13 | 33 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 2 | 4 | 2 | 10 | 14 | 31 |
Show 269 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Status epilepticus | D013226 | EFO_0008526 | G41 | 1 | 2 | 9 | — | 4 | 15 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 9 | 3 | — | 1 | 11 |
| Traumatic stress disorders | D040921 | — | — | — | 6 | 2 | — | 1 | 8 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | — | — | 2 | — | 6 | 8 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | 2 | — | 5 | 7 |
| Adenoma | D000236 | — | — | — | — | 1 | — | 5 | 6 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 3 | — | 3 | — | — | 6 |
| Suicide | D013405 | — | — | — | 3 | 1 | — | 1 | 5 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | 4 | 5 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 4 | — | 1 | — | — | 5 |
Show 66 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 6 | 2 | — | — | — | 7 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 4 | 2 | — | — | — | 5 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 4 | 1 | — | — | — | 5 |
| Eczema | D004485 | HP_0000964 | L30.9 | 4 | 1 | — | — | — | 5 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | 4 | 1 | — | — | — | 5 |
| Operative surgical procedures | D013514 | — | — | — | 2 | — | — | 2 | 4 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | 3 | — | — | 1 | 4 |
| Leukemia | D007938 | — | C95 | 3 | 2 | — | — | — | 3 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 2 | — | — | — | 3 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 2 | — | — | — | 3 |
Show 47 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | 26 | — | — | — | 3 | 29 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 11 | — | — | — | — | 11 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 6 | — | — | — | 1 | 7 |
| Overweight | D050177 | — | E66.3 | 6 | — | — | — | — | 6 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 6 | — | — | — | — | 6 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | 4 | 5 |
| Amnesia | D000647 | EFO_1001454 | F44.0 | 3 | — | — | — | 2 | 5 |
| Melanoma | D008545 | — | — | 4 | — | — | — | — | 4 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 3 | — | — | — | 1 | 4 |
| Hepatitis c | D006526 | — | B19.2 | 4 | — | — | — | — | 4 |
Show 103 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | — | 5 | 5 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 3 | 3 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | — | — | — | — | 3 | 3 |
| Cardiopulmonary bypass | D002315 | — | — | — | — | — | — | 3 | 3 |
| Airway management | D058109 | — | — | — | — | — | — | 3 | 3 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 3 | 3 |
| Epidural analgesia | D015360 | — | — | — | — | — | — | 2 | 2 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 2 | 2 |
| Thoracic surgical procedures | D019616 | — | — | — | — | — | — | 2 | 2 |
| Anterograde amnesia | D020324 | — | R41.1 | — | — | — | — | 2 | 2 |
Show 169 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Midazolam |
| INN | midazolam |
| Description | Midazolam is an imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. It has a role as a GABAA receptor agonist, an anticonvulsant, an anxiolytic drug, an apoptosis inducer, an antineoplastic agent, a muscle relaxant, a sedative, a general anaesthetic and a central nervous system depressant. It is an organochlorine compound, an imidazobenzodiazepine and a member of monofluorobenzenes. |
| Classification | Small molecule |
| Drug class | Benzodiazepine |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2 |
Identifiers
| PDB | — |
| CAS-ID | 59467-70-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL655 |
| ChEBI ID | 6931 |
| PubChem CID | 4192 |
| DrugBank | DB00683 |
| UNII ID | R60L0SM5BC (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CYP3A4
CYP3A4
Organism
Homo sapiens
Gene name
CYP3A4
Gene synonyms
CYP3A3
NCBI Gene ID
Protein name
cytochrome P450 3A4
Protein synonyms
1,4-cineole 2-exo-monooxygenase, 1,8-cineole 2-exo-monooxygenase, Albendazole monooxygenase (sulfoxide-forming), Albendazole sulfoxidase, Cholesterol 25-hydroxylase, CYPIIIA3, CYPIIIA4, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, cytochrome P450, family 3, subfamily A, polypeptide 4, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, Cytochrome P450-PCN1, glucocorticoid-inducible P450, Nifedipine oxidase, P450-III, steroid inducible, Quinine 3-monooxygenase, taurochenodeoxycholate 6-alpha-hydroxylase
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Midazolam
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 66,040 documents
View more details
Safety
Black-box Warning
Black-box warning for: Midazolam, Midazolam hydrochloride, Midazolam in sodium chloride, N/a, Nayzilam, Seizalam
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,675 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use